Dechra acquires worldwide rights to canine lymphoma treatment
Pharmaceutical giant Dechra has acquired the worldwide rights to verdinexor, a novel treatment of all forms and stages of canine lymphoma from Anivive Lifesciences.
Dechra Pharmaceuticals
3,866.00p
08:01 16/01/24
FTSE 100
8,173.02
13:09 31/12/24
FTSE 350
4,510.61
12:59 31/12/24
FTSE All-Share
4,467.80
13:14 31/12/24
Pharmaceuticals & Biotechnology
20,085.55
12:59 31/12/24
Dechra said on Tuesday that under the terms of the agreement, it will acquire the global product rights and the first right of refusal for other species along with the trademark of Laverdia.
The FTSE 100-listed firm said the product, currently sold as Laverdia-CA1 in the USA, was a novel oral selective inhibitor of nuclear export drug and the first oral tablet for canine lymphoma.
Dechra will acquire the worldwide marketing rights, the rights to the intellectual property, the marketing authorisations, when granted, and associated regulatory documentation, supply contracts with third parties in relation to the raw material, and manufacture of the finished product.
The drug was conditionally approved by the FDA Center for Veterinary Medicine on 11 January 2021.
Chief executive Ian Page said: "We are delighted to acquire the worldwide rights to Laverdia. Its addition to our portfolio will expand Dechra into a new, niche therapy area, while also offering veterinarians and dog owners a simple to use, effective medication for lymphoma that extends the time a family has with their pet."
As of 0825 GMT, Dechra shares were up 2.98% at 4,428.0p.